Massachusetts Panel Urges Action on Xylazine and Emerging Drug Threats
State commission recommends expanding low-barrier treatment and harm reduction as xylazine gives way to medetomidine in the illicit drug supply.
May 8, 20265 min read
Blog & News
Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
AllTreatment AccessOpioid CrisisFederal Policytreatment-accessClinical ResearchHarm ReductionSubstance Use DisorderOpioid AddictionMental HealthState LegislationMedication-Assisted Treatmentopioid-crisisclinical-researchfederal-policyFundingopioid-addictionsubstance-use-disorderData Reportsmedication-assisted-treatmentmental-healthdata-reportsharm-reductionstate-legislationPsychedelicsClinical TrialsfundingAlcohol Addictionclinical-trialsbehavioral-therapyBuprenorphinepsychedelicsbuprenorphineBehavioral Therapydigital-healthalcohol-addictionGambling AddictionStimulant AddictionTelehealthtelehealthDigital HealthPeer RecoveryComplementary TherapyMedication Assisted Treatmentrural-healthcareSubstance-Use-DisorderSynthetic Opioidsgambling-addictionYouthFentanylMarijuana Dependenceadolescent-healthmarijuana-dependencepeer-recoveryyouthmobile-healthstimulant-addictionFederal-PolicyClinical-TrialsClinical-ResearchLitigationInternationalTreatment OptionsRecoveryRehabilitationResearch
Tennessee Enacts HOPE Act, Clearing Path for Ibogaine Clinical Trials
Tennessee becomes latest state to legalize FDA-approved ibogaine research, joining Texas and Arizona in studying the psychedelic for PTSD and opioid addiction treatment.
May 8, 20265 min read
New Hampshire Secures $29.5 Million from Purdue Pharma Settlement to Combat Opioid Crisis
New Hampshire will receive $29.5 million over 10 years from the Purdue Pharma settlement to fund prevention, treatment, and recovery programs.
May 7, 20263 min read
Texas Prepares to Launch Medical Psilocybin Program by End of 2026, Joining National Push for Psychedelic Therapy
Texas is developing a medical psilocybin program to treat depression, PTSD, and substance use disorders, with support from Trump's executive order and FDA fast-tracking.
May 7, 20265 min read
FDA Fast-Tracks CS-1103: A New Weapon Against Fentanyl Overdoses
FDA grants Fast Track designation to CS-1103, a first-in-class molecule that binds and clears fentanyl from the body, potentially revolutionizing overdose treatment.
May 6, 20264 min read
Inside Trump's 2026 National Drug Control Strategy: Wastewater Testing, AI Surveillance, and Faith-Based Recovery
The White House releases its 2026 National Drug Control Strategy, introducing controversial new surveillance tools and emphasizing faith-based approaches to addiction treatment.
May 6, 20265 min read
$7.4 Billion Purdue-Sackler Opioid Settlement Becomes Legally Effective, Ending Decade of Litigation
Landmark settlement bans Sackler family from U.S. opioid sales permanently and delivers $7.4 billion for addiction treatment, prevention, and recovery over 15 years.
May 4, 20267 min read
AHA Presses Congress for Rural Healthcare Workforce Funding as Crisis Deepens
American Hospital Association urges federal investment in loan repayment and training programs to address severe provider shortages affecting 75% of rural health professional shortage areas.
May 3, 20267 min read
SAMHSA Bans Federal Funding for Fentanyl Test Strips and Clean Syringes in Major Policy Shift
Trump administration reverses harm reduction policy, prohibiting federal funds for drug testing supplies and sterile syringes while emphasizing abstinence-based recovery approaches.
May 3, 20268 min read